United Therapeutics Corp earnings per share and revenue
On Oct 29, 2025, UTHR reported earnings of 7.16 USD per share (EPS) for Q3 25, missing the estimate of 7.33 USD, resulting in a -2.35% surprise. Revenue reached 799.50 million, compared to an expected 831.21 million, with a -3.82% difference. The market reacted with a +9.63% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 15 analysts forecast an EPS of 7.00 USD, with revenue projected to reach 832.86 million USD, implying an decrease of -2.23% EPS, and increase of 4.17% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
What were United Therapeutics Corp's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, United Therapeutics Corp reported EPS of $7.16, missing estimates by -2.35%, and revenue of $799.50M, -3.82% below expectations.
How did the market react to United Therapeutics Corp's Q3 2025 earnings?
The stock price moved up 9.63%, changed from $415.34 before the earnings release to $455.32 the day after.
When is United Therapeutics Corp expected to report next?
The next earning report is scheduled for Feb 25, 2026.
What are the forecasts for United Therapeutics Corp's next earnings report?
Based on 15
analysts, United Therapeutics Corp is expected to report EPS of $7.00 and revenue of $832.86M for Q4 2025.